Trial reportFrontiers in cardiovascular medicine2025
SGLT2 inhibitor short-term efficacy and SYNTAX score association in coronary heart disease retinopathy: a propensity score matching study.
Trial report in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Type 2 diabetes (T2DM) and hypertension (HTN) are key risk factors for retinopathy and often coexist with coronary heart disease (CHD). While AI-based retinal imaging predicts CHD risk, links between CHD lesion complexity and retinopathy, and potential benefits of Sodium-Glucose Cotransporter-2 (SGLT2) inhibitors on retinopathy in CHD patients with T2DM, lack sufficient evidence. Methods: This case-control study (Jan 2024-Mar 2025) enrolled 642 subjects from Beijing Tongren Hospital (affiliated with Capital Medical University). Retinal imaging data were analyzed. Propensity score matching (PSM) created baseline and optimized datasets. Univariate/multivariate logistic regression assessed if CHD increases retinopathy risk in patients with T2DM, HTN, or both. Pearson correlation evaluated associations between CHD lesion complexity (SYNTAX score) and retinal parameters. Stratified analysis assessed SGLT2 inhibitor effects on retinopathy in hypertensive-diabetic subgroups with/without CHD. The analysis of SGLT2 inhibitor efficacy was based on a retrospective cohort study of drug utilization rather than a prospective randomized intervention. Results: Within the hypertensive-diabetic cohort, CHD patients ( Conclusion: CHD elevates retinopathy risk in patients with T2DM, HTN, or both. Coronary lesion complexity correlates with retinal microvascular changes. SGLT2 inhibitors demonstrate a potential protective effect against some aspects of retinopathy development.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.